SMT D002Alternative Names: DL 06003; SMT-D002
Latest Information Update: 14 Mar 2013
At a glance
- Originator Summit plc
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Seborrhoeic dermatitis